GlaxoSmithKline and Flamel Technologies in license agreement
GlaxoSmithKline has entered into an agreement with French biopharmaceutical company Flamel Technologies to license its controlled-release Micropump technology to develop a new formulation for an undisclosed existing product.
GlaxoSmithKline has entered into an agreement with French biopharmaceutical company Flamel Technologies to license its controlled-release Micropump technology to develop a new formulation for an undisclosed existing product.
Flamel will receive an upfront payment of US$2m (€1.9m), additional milestone pay-ments, and royalties on product sales, amounting to some $45m (€42m) by the end of the first year following launch. Flamel may also participate in the manufacture of product. Additional terms of the agreement have not been disclosed.
Flamel Technologies is principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Medusa nanoparticulate technology is designed to deliver therapeutic proteins.
Dr Gerard Soula, president and ceo of Flamel, said, 'We are confident of the potential of Micropump technology for these large, and still growing, markets. This is our second license agreement with GSK within the past nine months, based on Micropump technology. It confirms the common interest of the two companies to work together.'